|
David J. Schneider1; Yabing Chen2; Burton E. Sobel1
1Department of Medicine and the Cardiovascular Research Institute, University of Vermont, Burlington, Vermont, USA; 2Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Plasminogen activator inhibitor type-1 (PAI-1), an inhibitor of plasminogen activators, inhibits formation of plasmin and plasmin- mediated proteolysis.Apoptosis, or programmed cell death, is a potentially important phenomenon in mediating overall cell death.This review focuses on the influence of PAI-1 on apoptosis. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. Mechanisms by which PAI-1 may render a cell resistant to apoptosis include its ability to inhibit generation of plasmin,its ability to inhibit caspase 3, and its ability to inhibit cell adhesion mediated by vitronectin. Inhibition of caspase 3 by PAI-1 may divert intracellular signalling from induction of apoptosis to induction of proliferation.
cancer, plasminogen activator inhibitor, apoptosis, vascular remodelling
| 1. | ||
Ulrik A. Lademann; Maria Unni Rømer Thrombosis and Haemostasis 2008 100 6: 1041-1046 http://dx.doi.org/10.1160/TH08-04-0266 | ||
| 2. | ||
Federico Jorge Bottaro1,3, Maria Cristina Elizondo1, Carlos Doti2,3, Julio Enrique Bruetman1, Pablo Diego Perez Moreno1, Eduardo Oscar Bullorsky2,3, Jose Manuel Ceresetto2,3 Thrombosis and Haemostasis 2008 99 6: 1104-1111 http://dx.doi.org/10.1160/TH07-12-0759 | ||
| 3. | ||
A. Dorn1, A. Rohde2 Die Psychiatrie 2008 5 2: 83-90 | ||